| Year |
Citation |
Score |
| 2024 |
Frame G, Leong H, Haas R, Huang X, Wright J, Emmenegger U, Downes M, Boutros PC, Kislinger T, Liu SK. Targeting PLOD2 suppresses invasion and metastatic potential in radiorecurrent prostate cancer. Bjc Reports. 2: 60. PMID 39184453 DOI: 10.1038/s44276-024-00085-3 |
0.36 |
|
| 2024 |
Haas R, Frame G, Khan S, Neilsen BK, Hong BH, Yeo CPX, Yamaguchi TN, Ong EHW, Zhao W, Carlin B, Yeo ELL, Tan KM, Bugh YZ, Zhu C, Hugh-White R, ... ... Liu SK, et al. The Proteogenomics of Prostate Cancer Radioresistance. Cancer Research Communications. PMID 39166898 DOI: 10.1158/2767-9764.CRC-24-0292 |
0.374 |
|
| 2024 |
Hudson JM, Loblaw A, McGuffin M, Chung HT, Tseng CL, Helou J, Cheung P, Szumacher E, Liu S, Zhang L, Deabreu A, Mamedov A, Morton G. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy: A 9-year update. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 198: 110381. PMID 38879130 DOI: 10.1016/j.radonc.2024.110381 |
0.302 |
|
| 2023 |
Glicksman RM, Loblaw A, Morton G, Vesprini D, Szumacher E, Chung HT, Chu W, Liu SK, Tseng CL, Correa R, Deabreu A, Mamedov A, Zhang L, Cheung P. Randomized trial of concomitant hypofractionated IMRT boost versus conventional fractionated IMRT boost for localized high-risk prostate cancer (pHART2-RCT). International Journal of Radiation Oncology, Biology, Physics. PMID 37979707 DOI: 10.1016/j.ijrobp.2023.11.006 |
0.312 |
|
| 2023 |
Ong WL, Cheung P, Chung H, Chu W, Detsky J, Liu S, Morton G, Szumacher E, Tseng CL, Vesprini D, Davidson M, Ravi A, McGuffin M, Zhang L, Mamedov A, et al. To boost or not to boost - pooled analyses from two-fraction stereotactic ablative radiotherapy (SABR) trials for localised prostate cancer. International Journal of Radiation Oncology, Biology, Physics. PMID 37419394 DOI: 10.1016/j.ijrobp.2023.06.250 |
0.33 |
|
| 2023 |
Mesci A, Ahmadi E, Ali A, Gouran-Savadkoohi M, Evelyn Tsakiridis E, Biziotis OD, Chow T, Kapoor A, Sur M, Steinberg GR, Liu S, Zukotynski K, Tsakiridis T. F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer. Clinical and Translational Radiation Oncology. 39: 100583. PMID 36713978 DOI: 10.1016/j.ctro.2023.100583 |
0.314 |
|
| 2022 |
Correa RJM, Morton G, Chung HT, Tseng CL, Cheung P, Chu W, Liu SK, McGuffin M, Shahid A, Davidson M, Ravi A, Helou J, Alayed Y, Zhang L, Mamedov A, et al. Two-fraction stereotactic ablative radiotherapy (SABR) versus two-fraction high dose rate (HDR) brachytherapy for localized prostate cancer: Does dose heterogeneity matter? Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 169: 51-56. PMID 35151715 DOI: 10.1016/j.radonc.2022.02.007 |
0.331 |
|
| 2021 |
Musunuru HB, Cheung P, Vesprini D, Liu SK, Chu W, Chung HT, Morton G, Deabreu A, Davidson M, Ravi A, Helou J, Ho L, Zhang L, Loblaw A. Gantry-based 5-fraction Elective Nodal Irradiation in Unfavorable-Risk Prostate Cancer: Outcomes from 2 Prospective Studies comparing SABR Boost with MR Dose Painted HDR Brachytherapy Boost. International Journal of Radiation Oncology, Biology, Physics. PMID 34637882 DOI: 10.1016/j.ijrobp.2021.10.003 |
0.339 |
|
| 2021 |
Glicksman RM, Liu SK, Cheung P, Vesprini D, Chu W, Chung HT, Morton G, Deabreu A, Davidson M, Ravi A, Bindu Musunuru H, Helou J, Ho L, Zhang L, Loblaw A. Elective nodal ultra hypofractionated radiation for prostate cancer: safety and efficacy from four prospective clinical trials. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 34487764 DOI: 10.1016/j.radonc.2021.08.017 |
0.337 |
|
| 2021 |
Khoo A, Liu LY, Nyalwidhe JO, Semmes OJ, Vesprini D, Downes MR, Boutros PC, Liu SK, Kislinger T. Proteomic discovery of non-invasive biomarkers of localized prostate cancer using mass spectrometry. Nature Reviews. Urology. PMID 34453155 DOI: 10.1038/s41585-021-00500-1 |
0.351 |
|
| 2021 |
Glicksman RM, Loblaw A, Morton G, Szumacher E, Chung HT, Vesprini D, Chu W, Liu SK, Choo R, Deabreu A, Mamedov A, Zhang L, Cheung P. Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localized high risk prostate cancer: Long term results from a prospective clinical trial. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 34324914 DOI: 10.1016/j.radonc.2021.07.018 |
0.343 |
|
| 2021 |
Musunuru HB, Cheung P, Vesprini D, Liu SK, Chu W, Chung HT, Morton G, Deabreu A, Davidson M, Ravi A, Helou J, Ho L, Zhang L, Loblaw A. Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): efficacy, toxicity and quality of life. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 34089752 DOI: 10.1016/j.radonc.2021.05.024 |
0.314 |
|
| 2020 |
Corkum M, Loblaw A, Hasan Y, Chung HT, Tseng CL, McGuffin M, Cheung P, Szumacher E, Liu S, Chu W, Zhang L, Mamedov A, Morton G. Prostate high dose-rate brachytherapy as monotherapy for prostate cancer: late toxicity and patient reported outcomes from a randomized phase II clinical trial. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 33359269 DOI: 10.1016/j.radonc.2020.12.021 |
0.305 |
|
| 2020 |
Alayed Y, Loblaw A, McGuffin M, Chung HT, Tseng CL, D'Alimonte L, Cheung P, Liu S, Chu W, Szumacher E, Helou J, Ravi A, Haider M, Mamedov A, Zhang L, et al. Single-fraction HDR brachytherapy as monotherapy in low and intermediate risk prostate cancer: outcomes from two clinical trials with and without an MRI-guided boost. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 32918971 DOI: 10.1016/J.Radonc.2020.09.007 |
0.408 |
|
| 2020 |
Hoey C, Jeyapala R, Boutros PC, Bapat B, Liu SK. Urinary biomarkers in prostate cancer: to the miRnome and beyond. Translational Andrology and Urology. 9: 843-845. PMID 32420197 DOI: 10.21037/Tau.2019.11.25 |
0.412 |
|
| 2020 |
Detsky JS, Ghiam AF, Mamedov A, Commisso K, Commisso A, Zhang L, Liu S, Klotz L, Loblaw A, Vesprini D. Impact of Biopsy Compliance on Outcomes for Patients on Active Surveillance for Prostate Cancer. The Journal of Urology. 101097JU000000000000. PMID 32330406 DOI: 10.1097/Ju.0000000000001091 |
0.418 |
|
| 2020 |
Labbé M, Hoey C, Ray J, Potiron V, Supiot S, Liu SK, Fradin D. microRNAs identified in prostate cancer: Correlative studies on response to ionizing radiation. Molecular Cancer. 19: 63. PMID 32293453 DOI: 10.1186/S12943-020-01186-6 |
0.423 |
|
| 2020 |
Morton G, McGuffin M, Chung HT, Tseng CL, Helou J, Ravi A, Cheung P, Szumacher E, Liu S, Chu W, Zhang L, Mamedov A, Loblaw A. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 146: 90-96. PMID 32146259 DOI: 10.1016/J.Radonc.2020.02.009 |
0.413 |
|
| 2020 |
Alayed Y, Davidson M, Liu S, Chu W, Tseng CL, Cheung P, Vesprini D, Chung H, Morton G, Musunuru HB, Ravi A, Korol R, Deabreu A, Ho L, Commisso K, et al. Evaluating the tolerability of a simultaneous focal boost to the gross tumour in prostate SABR: a toxicity and quality of life comparison of two prospective trials. International Journal of Radiation Oncology, Biology, Physics. PMID 31987962 DOI: 10.1016/J.Ijrobp.2019.12.044 |
0.393 |
|
| 2020 |
Loblaw A, Cheung P, Vesprini D, Liu SK, Chu W, Chung HT, Morton G, Musunuru B, Deabreu A, Davidson M, Ravi A, Helou J, Ho L, Zhang L. Stereotactic radiotherapy +/- HDR boost for unfavorable-risk prostate cancer: Comparison of efficacy, survival, and late toxicity outcomes. Journal of Clinical Oncology. 38: 372-372. DOI: 10.1200/Jco.2020.38.6_Suppl.372 |
0.455 |
|
| 2020 |
Loblaw A, Musunuru B, Cheung P, Vesprini D, Liu SK, Chu W, Chung HT, Morton G, Deabreu A, Davidson M, Ravi A, Helou J, Ho L, Zhang L. Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): Efficacy, survival, and late toxicity outcomes. Journal of Clinical Oncology. 38: 328-328. DOI: 10.1200/Jco.2020.38.6_Suppl.328 |
0.447 |
|
| 2020 |
Alayed Y, Davidson M, Chu W, Liu SK, Tseng C, Cheung P, Vesprini D, Chung HT, Morton G, Musunuru HB, Ravi A, Korol R, Deabreu A, Commisso K, Bhounr Z, et al. Evaluating the tolerability of a simultaneous focal boost to the gross tumor in prostate SABR: A toxicity and quality-of-life comparison of two prospective trials. Journal of Clinical Oncology. 38: 319-319. DOI: 10.1200/Jco.2020.38.6_Suppl.319 |
0.408 |
|
| 2019 |
Ray J, Haughey C, Hoey C, Jeon J, Murphy R, Dura-Perez L, McCabe N, Downes M, Jain S, Boutros PC, Mills IG, Liu SK. miR-191 promotes radiation resistance of prostate cancer through interaction with RXRA. Cancer Letters. PMID 31874245 DOI: 10.1016/J.Canlet.2019.12.025 |
0.422 |
|
| 2019 |
Alayed Y, Davidson M, Quon H, Cheung P, Chu W, Chung HT, Vesprini D, Ong A, Chowdhury A, Liu SK, Panjwani D, Helou J, Musunuru HB, Pang G, Korol R, et al. Dosimetric predictors of toxicity and quality of life following prostate stereotactic ablative radiotherapy. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 144: 135-140. PMID 31809979 DOI: 10.1016/J.Radonc.2019.11.017 |
0.404 |
|
| 2019 |
Martell K, Mendez LC, Chung HT, Tseng CL, Alayed Y, Cheung P, Liu S, Vesprini D, Chu W, Wronski M, Szumacher E, Ravi A, Loblaw A, Morton G. Results of 15 Gy HDR-BT boost plus EBRT in intermediate-risk prostate cancer: Analysis of over 500 patients. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 31522882 DOI: 10.1016/J.Radonc.2019.08.017 |
0.445 |
|
| 2019 |
Ray J, Hoey C, Huang X, Jeon J, Taeb S, Downes MR, Boutros PC, Liu SK. MicroRNA‑198 suppresses prostate tumorigenesis by targeting MIB1. Oncology Reports. PMID 31322262 DOI: 10.3892/Or.2019.7234 |
0.468 |
|
| 2019 |
Jeon J, Olkhov-Mitsel E, Xie H, Yao CQ, Zhao F, Jahangiri S, Cuizon C, Scarcello S, Jeyapala R, Watson JD, Fraser M, Ray J, Commisso K, Loblaw A, Fleshner NE, ... ... Liu S, et al. Temporal stability and prognostic biomarker potential of the prostate cancer urine transcriptome. Journal of the National Cancer Institute. PMID 31161221 DOI: 10.1093/Jnci/Djz112 |
0.412 |
|
| 2019 |
Hoey C, Ahmed M, Fotouhi Ghiam A, Vesprini D, Huang X, Commisso K, Commisso A, Ray J, Fokas E, Loblaw DA, He HH, Liu SK. Circulating miRNAs as non-invasive biomarkers to predict aggressive prostate cancer after radical prostatectomy. Journal of Translational Medicine. 17: 173. PMID 31122242 DOI: 10.1186/S12967-019-1920-5 |
0.473 |
|
| 2019 |
Martell K, Mendez LC, Chung H, Tseng CL, Zhang L, Alayed Y, Liu S, Vesprini D, Chu W, Paudel M, Cheung P, Szumacher E, Ravi A, Loblaw A, Morton G. Absolute percentage of biopsied tissue positive for Gleason pattern 4 disease (APP4) appears predictive of disease control after high dose rate brachytherapy and external beam radiotherapy in intermediate risk prostate cancer. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 135: 170-177. PMID 31015164 DOI: 10.1016/J.Radonc.2019.03.007 |
0.416 |
|
| 2019 |
Mesci A, Lucien F, Huang X, Wang EH, Shin D, Meringer M, Hoey C, Ray J, Boutros PC, Leong HS, Liu SK. RSPO3 is a prognostic biomarker and mediator of invasiveness in prostate cancer. Journal of Translational Medicine. 17: 125. PMID 30987640 DOI: 10.1186/S12967-019-1878-3 |
0.437 |
|
| 2019 |
Hoey C, Liu SK. Circulating blood miRNAs for prostate cancer risk stratification: miRroring the underlying tumor biology with liquid biopsies. Research and Reports in Urology. 11: 29-42. PMID 30881943 DOI: 10.2147/Rru.S165625 |
0.411 |
|
| 2019 |
Zhao F, Vesprini D, Liu RSC, Olkhov-Mitsel E, Klotz LH, Loblaw A, Liu SK, Bapat B. Combining urinary DNA methylation and cell-free microRNA biomarkers for improved monitoring of prostate cancer patients on active surveillance. Urologic Oncology. PMID 30777394 DOI: 10.1016/J.Urolonc.2019.01.031 |
0.428 |
|
| 2019 |
Chen S, Huang V, Xu X, Livingstone J, Soares F, Jeon J, Zeng Y, Hua JT, Petricca J, Guo H, Wang M, Yousif F, Zhang Y, Donmez N, Ahmed M, ... ... Liu S, et al. Widespread and Functional RNA Circularization in Localized Prostate Cancer. Cell. 176: 831-843.e22. PMID 30735634 DOI: 10.1016/J.Cell.2019.01.025 |
0.362 |
|
| 2019 |
Bhandari V, Hoey C, Liu LY, Lalonde E, Ray J, Livingstone J, Lesurf R, Shiah YJ, Vujcic T, Huang X, Espiritu SMG, Heisler LE, Yousif F, Huang V, Yamaguchi TN, ... ... Liu SK, et al. Molecular landmarks of tumor hypoxia across cancer types. Nature Genetics. PMID 30643250 DOI: 10.1038/S41588-018-0318-2 |
0.306 |
|
| 2019 |
Vinayak B, Liu L, Espirritu S, Lalonde E, Yamaguchi T, Heisler L, Livingstone J, Huang V, Shiah Y, Sabelnykova V, Yousif F, Fraser M, Chua M, Van Der Kwast T, Liu SK, et al. The molecular hallmarks and clinical consequences of tumor hypoxia in prostate cancer. Journal of Clinical Oncology. 37: 81-81. DOI: 10.1200/Jco.2019.37.7_Suppl.81 |
0.461 |
|
| 2019 |
Detsky J, Ghiam AF, Mamedov A, Commisso K, Commisso A, Klotz L, Liu SK, Loblaw A, Vesprini D. Impact of compliance on outcomes for patients on active surveillance for prostate cancer. Journal of Clinical Oncology. 37: 36-36. DOI: 10.1200/Jco.2019.37.7_Suppl.36 |
0.423 |
|
| 2019 |
Alayed Y, Cheung P, Vesprini D, Liu SK, Chu W, Chung HT, Musunuru HB, Davidson M, Ravi A, Ho L, Deabreu A, D'alimonte L, Bhounr Z, Zhang L, Commisso K, et al. SABR in high-risk prostate cancer: Outcomes from two prospective clinical trials with and without elective nodal irradiation. Journal of Clinical Oncology. 37: 3-3. DOI: 10.1200/Jco.2019.37.7_Suppl.3 |
0.439 |
|
| 2019 |
Mesci A, Liu S, Chung H. 99 Serum Cytokine Profiling as a Potential Biomarker in Intermediate Risk Prostate Cancer: An Exploratory Study Radiotherapy and Oncology. 139. DOI: 10.1016/S0167-8140(19)33391-2 |
0.426 |
|
| 2019 |
Mekhaeil B, Zacharidis P, Tsakiridis E, Biziotis O, Broadfield L, Menjolian G, Mathurin T, Farrell T, Muti P, Liu S, Steinberg G, Tsakiridis T. 167 The New Diabetes Drug Canagliflozin Enhances the Response of Prostate Cancer to Radiotherapy Radiotherapy and Oncology. 139. DOI: 10.1016/S0167-8140(19)33223-2 |
0.384 |
|
| 2019 |
Detsky J, Ghiam AF, Klotz L, Liu S, Loblaw A, Vesprini D. 12 Impact of Compliance on Outcomes for Patients on Active Surveillance for Prostate Cancer Radiotherapy and Oncology. 139. DOI: 10.1016/S0167-8140(19)33171-8 |
0.428 |
|
| 2019 |
Mendez L, Martell K, Chung H, Tseng C, Alayed Y, Cheung P, Liu S, Vesprini D, Chu W, Szumacher E, Ravi A, Loblaw A, Morton G. OC-0288 Long-term results of 15Gy HDRBT boost in intermediate risk-prostate cancer:Analysis of 500 + patients Radiotherapy and Oncology. 133. DOI: 10.1016/S0167-8140(19)30708-X |
0.422 |
|
| 2019 |
Cheung P, Morton G, Chung HT, Vesprini D, Chu W, Liu SK, Tseng CL, Sahgal A, Soliman H, Myrehaug SD, Szumacher E, Chung P, Helou J, Emmenegger U, Erler D, et al. Comprehensive Stereotactic Radiotherapy for Oligometastatic Prostate Cancer (CROP) International Journal of Radiation Oncology Biology Physics. 105. DOI: 10.1016/J.Ijrobp.2019.06.1886 |
0.456 |
|
| 2018 |
Mesci A, Liu SK, Loblaw DA. Spurious elevation of Prostate-specific antigen associated with shingles in a prostate cancer patient undergoing active surveillance. Clinical Case Reports. 6: 2338-2340. PMID 30564325 DOI: 10.1002/Ccr3.1838 |
0.453 |
|
| 2018 |
Alayed Y, Cheung P, Vesprini D, Liu S, Chu W, Chung H, Musunuru HB, Davidson M, Ravi A, Ho L, Deabreu A, D'Alimonte L, Bhounr Z, Zhang L, Commisso K, et al. SABR in high risk prostate cancer: outcomes from two prospective clinical trials with and without elective nodal irradiation. International Journal of Radiation Oncology, Biology, Physics. PMID 30445172 DOI: 10.1016/J.Ijrobp.2018.11.011 |
0.449 |
|
| 2018 |
Hahn E, Liu SK, Vesprini D, Xu B, Downes MR. Immune infiltrates and PD-L1 expression in treatment-naïve acinar prostatic adenocarcinoma: an exploratory analysis. Journal of Clinical Pathology. PMID 30257853 DOI: 10.1136/Jclinpath-2018-205404 |
0.371 |
|
| 2018 |
Musunuru HB, D'Alimonte L, Davidson M, Ho L, Cheung P, Vesprini D, Liu S, Chu W, Chung H, Ravi A, Deabreu A, Zhang L, Commisso K, Loblaw DA. Phase I/II Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation in Patients with High-Risk Prostate Cancer (SATURN): Early Toxicity and Quality of Life. International Journal of Radiation Oncology, Biology, Physics. PMID 30071295 DOI: 10.1016/J.Ijrobp.2018.07.2005 |
0.416 |
|
| 2018 |
Loblaw A, Liu S, Cheung P. Stereotactic ablative body radiotherapy in patients with prostate cancer. Translational Andrology and Urology. 7: 330-340. PMID 30050794 DOI: 10.21037/Tau.2018.01.18 |
0.454 |
|
| 2018 |
Lam WW, Oakden W, Murray L, Klein J, Iorio C, Screaton RA, Koletar MM, Chu W, Liu SK, Stanisz GJ. Differentiation of Normal and Radioresistant Prostate Cancer Xenografts Using Magnetization Transfer-Prepared MRI. Scientific Reports. 8: 10447. PMID 29992999 DOI: 10.1038/S41598-018-28731-0 |
0.336 |
|
| 2018 |
Hoey C, Ray J, Jeon J, Huang X, Taeb S, Ylanko J, Andrews DW, Boutros PC, Liu SK. MiRNA-106a and prostate cancer radioresistance: a novel role for LITAF in ATM regulation. Molecular Oncology. PMID 29845714 DOI: 10.1002/1878-0261.12328 |
0.376 |
|
| 2018 |
Lorentz J, Liu SK, Vesprini D. Male Oncology Research and Education program for men at high risk for prostate cancer. Current Oncology (Toronto, Ont.). 25: 170-175. PMID 29719433 DOI: 10.3747/Co.25.3818 |
0.416 |
|
| 2018 |
Ray J, Hoey C, Huang X, Boutros PC, Liu SK. Microrna-198: A novel tumor suppressor in prostate cancer. Journal of Clinical Oncology. 36: 92-92. DOI: 10.1200/Jco.2018.36.6_Suppl.92 |
0.388 |
|
| 2018 |
Hoey C, Ray J, Huang X, Jeon J, Boutros PC, Liu SK. Overcoming miR-106a induced radioresistance in prostate cancer: Targeting senescence with KU-55933. Journal of Clinical Oncology. 36: 77-77. DOI: 10.1200/Jco.2018.36.6_Suppl.77 |
0.367 |
|
| 2018 |
Mesci A, Huang X, Shin D, Hoey C, Ray J, Liu SK. Loss of RSPO3 as a potential mechanism of greater invasiveness in prostate cancer. Journal of Clinical Oncology. 36: 333-333. DOI: 10.1200/Jco.2018.36.6_Suppl.333 |
0.429 |
|
| 2017 |
Liu RSC, Olkhov-Mitsel E, Jeyapala R, Zhao F, Commisso K, Klotz L, Loblaw A, Liu SK, Vesprini D, Fleshner NE, Bapat B. Assessment of serum microRNA biomarkers for predicting reclassification of prostate cancer patients on active surveillance. The Journal of Urology. PMID 29246734 DOI: 10.1016/J.Juro.2017.12.006 |
0.435 |
|
| 2017 |
Ghiam AF, Vesprini D, Liu SK. Long non-coding RNAs: new frontiers for advancing personalized cancer medicine in prostate cancer. Translational Andrology and Urology. 6: 326-330. PMID 28540248 DOI: 10.21037/Tau.2017.03.06 |
0.422 |
|
| 2017 |
Musunuru HB, Deabreu A, Davidson M, Ravi A, Helou JA, Ho L, Cheung P, Vesprini D, Liu SK, Chu W, Korol R, Chung HT, Mamedov A, Zhang L, Loblaw A. Pelvic SABR with HDR boost in intermediate- and high-risk prostate cancer (SPARE): Favorable early toxicity and quality-of-life outcomes. Journal of Clinical Oncology. 35: 60-60. DOI: 10.1200/Jco.2017.35.6_Suppl.60 |
0.459 |
|
| 2017 |
Hoey C, Ray J, Boutros P, Liu SK. Abstract 830: MiRNA-106a and LITAF are novel modulators of prostate cancer radioresistance Cancer Research. 77: 830-830. DOI: 10.1158/1538-7445.Am2017-830 |
0.397 |
|
| 2017 |
Musunuru HB, Deabreu A, Davidson M, Ravi A, Hlou J, Ho L, Cheung P, Vesprini D, Liu S, Chu W, Chung H, Zhang L, Loblaw A. EP-1341: Pelvic SABR with HDR boost in intermediate and high risk prostate cancer (spare): early results Radiotherapy and Oncology. 123. DOI: 10.1016/S0167-8140(17)31776-0 |
0.44 |
|
| 2017 |
Morton G, Chung H, McGuffin M, Ravi A, Liu S, Tseng E, Zhang L, Loblaw A. Prostate HDR Monotherapy: Initial Efficacy Results from a Randomized Trial of One versus Two Fractions Brachytherapy. 16. DOI: 10.1016/J.Brachy.2017.04.018 |
0.376 |
|
| 2016 |
Elzibak A, Loblaw A, Morton G, Vesprini D, Liu S, Chung H, Davidson M. SU-F-J-161: Prostate Contouring in Patients with Bilateral Hip Prostheses: Impact of Using Artifact-Reduced CT Images and MRI. Medical Physics. 43: 3444-3445. PMID 28048362 DOI: 10.1118/1.4956069 |
0.323 |
|
| 2016 |
Fotouhi Ghiam A, Taeb S, Huang X, Huang V, Ray J, Scarcello S, Hoey C, Jahangiri S, Fokas E, Loblaw A, Bristow RG, Vesprini D, Boutros P, Liu SK. Long non-coding RNA urothelial carcinoma associated 1 (UCA1) mediates radiation response in prostate cancer. Oncotarget. PMID 27902466 DOI: 10.18632/Oncotarget.13576 |
0.397 |
|
| 2016 |
Morton G, Chung HT, McGuffin M, Helou J, D'Alimonte L, Ravi A, Cheung P, Szumacher E, Liu S, Al-Hanaqta M, Zhang L, Mamedov A, Loblaw A. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 27823821 DOI: 10.1016/J.Radonc.2016.10.019 |
0.414 |
|
| 2016 |
Ghiam AF, Taeb S, Huang X, Jahangiri S, Ray J, Hoey C, Fokas E, Vesprini D, Bristow RG, Boutros PC, Liu SK. The Biological Role and Clinical Significance of Long Noncoding RNA Urothelial Carcinoma Associated 1 (UCA1) in Prostate Cancer (PCa). International Journal of Radiation Oncology, Biology, Physics. 96: S56. PMID 27675961 DOI: 10.1016/J.Ijrobp.2016.06.145 |
0.413 |
|
| 2016 |
Ghiam AF, Vesprini D, Taeb S, Jahangiri S, Huang X, Ray J, Hoey C, Loblaw DA, Fokas E, Liu SK. Serum Exosomal MicroRNAs (miRNAs) as Noninvasive Biomarkers to Guide Postoperative Radiation Therapy in Prostate Cancer (PCa) Patients Treated With Radical Prostatectomy (RP). International Journal of Radiation Oncology, Biology, Physics. 96: S186-S187. PMID 27675738 DOI: 10.1016/J.Ijrobp.2016.06.466 |
0.427 |
|
| 2016 |
Szumacher E, Dawdy K, Bonin K, Russell S, Ryzynski A, Harth T, Townsend C, Liu SK, Chu W, Cheung P, Chung HT, Morton G, Vesprini D, Loblaw DA, Cao X. Empowering Patients Through Education-Development and Evaluation of a Multimedia Patient Education Tool to Ensure Patient Preparedness for Planning CT Scan for Prostate Cancer (Randomized Study). International Journal of Radiation Oncology, Biology, Physics. 96: E506. PMID 27674874 DOI: 10.1016/J.Ijrobp.2016.06.1898 |
0.343 |
|
| 2016 |
Dawdy K, Bonin K, Russell S, Ryzynski A, Harth T, Townsend C, Liu S, Chu W, Cheung P, Chung H, Morton G, Vesprini D, Loblaw A, Cao X, Szumacher E. Developing and Evaluating Multimedia Patient Education Tools to Better Prepare Prostate-Cancer Patients for Radiotherapy Treatment (Randomized Study). Journal of Cancer Education : the Official Journal of the American Association For Cancer Education. PMID 27526692 DOI: 10.1007/S13187-016-1091-5 |
0.37 |
|
| 2016 |
Musunuru HB, Davidson M, Cheung P, Vesprini D, Liu S, Chung H, Chu W, Mamedov A, Ravi A, D'Alimonte L, Commisso K, Helou J, Deabreu A, Zhang L, Loblaw A. Predictive Parameters of Symptomatic Hematochezia Following 5-Fraction Gantry-Based SABR in Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics. 94: 1043-51. PMID 27026311 DOI: 10.1016/J.Ijrobp.2015.12.010 |
0.419 |
|
| 2016 |
Musunuru HB, Davidson M, Cheung P, Chu W, Chung HT, Vesprini D, Liu SK, Mamedov A, Ravi A, D'Alimonte L, Commissso K, Helou JA, Deabreu A, Zhang L, Loblaw A. Predictive parameters of symptomatic haematochezia following 5-fraction gantry-based SABR in prostate cancer. Journal of Clinical Oncology. 34: 79-79. DOI: 10.1200/Jco.2016.34.2_Suppl.79 |
0.366 |
|
| 2016 |
Musunuru HB, D'Alimonte L, Davidson M, Ho L, Cheung P, Vesprini D, Liu SK, Chu W, Chung HT, Ravi A, Deabreu A, Bhounr Z, Zhang L, Commissso K, Loblaw A. Phase I/II study of stereotactic ablative radiotherapy including regional lymph node irradiation for patients with high-risk prostate cancer (SATURN): Early results. Journal of Clinical Oncology. 34: 264-264. DOI: 10.1200/Jco.2016.34.2_Suppl.264 |
0.456 |
|
| 2016 |
Dawdy K, Bonin K, Russell S, Harth T, Townsend C, Liu S, Chu W, Cheung P, Chung H, Morton G, Vesprini D, Loblaw A, Cao X, Szumacher E. 192: Empowering Patients Through Education – Development and Evaluation of a Multimedia Patient Education Tool to Ensure Patient Preparedness for Planning CT Scan for Prostate Cancer (Randomized Study) Radiotherapy and Oncology. 120. DOI: 10.1016/S0167-8140(16)33591-5 |
0.343 |
|
| 2016 |
Ghiam AF, Vesprini D, Taeb S, Jahangiri S, Huang X, Ray J, Hoey C, Loblaw A, Fokas E, Liu SK. 78: CARO Fellowship Serum Exosomal Micrornas (MIRNAS) as Non-Invasive Biomarkers to Guide Post-Operative Radiotherapy in Prostate Cancer (PCA) Patients Treated with Radical Prostatectomy (RP) Radiotherapy and Oncology. 120. DOI: 10.1016/S0167-8140(16)33477-6 |
0.421 |
|
| 2016 |
Ghiam AF, Taeb S, Huang X, Jahangiri S, Ray J, Hoey C, Fokas EF, Vesprini D, Bristow R, Boutros P, Liu S. 25: CARO Fellowship the Biological Role and Clinical Significance of Long Non-Coding RNA Urothelial Carcinoma Associated 1 (UCA1) in Prostate Cancer (PCA) Radiotherapy and Oncology. 120: S10. DOI: 10.1016/S0167-8140(16)33424-7 |
0.404 |
|
| 2015 |
Karam I, Poon I, Lee J, Liu S, Higgins K, Enepekides D, Sahgal A, Lo SS. Stereotactic body radiotherapy for head and neck cancer: an addition to the armamentarium against head and neck cancer. Future Oncology (London, England). PMID 26414213 DOI: 10.2217/Fon.15.236 |
0.331 |
|
| 2015 |
Korpela E, Vesprini D, Liu SK. MicroRNA in radiotherapy: MiRage or miRador? British Journal of Cancer. 112: 777-782. PMID 25611301 DOI: 10.1038/Bjc.2015.6 |
0.406 |
|
| 2015 |
Musunuru HB, Davidson MT, D'Alimonte L, Ho L, Cheung P, Vesprini D, Liu S, Chu W, Chung HT, Ravi A, Deabreu A, Bhounr Z, Zhang L, Loblaw DA. Phase 1-2 Study of Stereotactic Ablative Radiation Therapy Including Regional Lymph Node Irradiation for Patients With High-Risk Prostate Cancer (SATURN) International Journal of Radiation Oncology Biology Physics. 93. DOI: 10.1016/J.Ijrobp.2015.07.1108 |
0.393 |
|
| 2014 |
Korpela E, Yohan D, Chin LC, Kim A, Huang X, Sade S, Van Slyke P, Dumont DJ, Liu SK. Vasculotide, an Angiopoietin-1 mimetic, reduces acute skin ionizing radiation damage in a preclinical mouse model. Bmc Cancer. 14: 614. PMID 25159192 DOI: 10.1186/1471-2407-14-614 |
0.301 |
|
| 2013 |
Tran E, Chow A, Goda T, Wong A, Blakely K, Rocha M, Taeb S, Hoang VC, Liu SK, Emmenegger U. Context-dependent role of ATG4B as target for autophagy inhibition in prostate cancer therapy. Biochemical and Biophysical Research Communications. 441: 726-31. PMID 24184480 DOI: 10.1016/J.Bbrc.2013.10.117 |
0.376 |
|
| 2013 |
Huang X, Taeb S, Jahangiri S, Emmenegger U, Tran E, Bruce J, Mesci A, Korpela E, Vesprini D, Wong CS, Bristow RG, Liu FF, Liu SK. miRNA-95 mediates radioresistance in tumors by targeting the sphingolipid phosphatase SGPP1. Cancer Research. 73: 6972-86. PMID 24145350 DOI: 10.1158/0008-5472.Can-13-1657 |
0.332 |
|
| 2013 |
Vesprini D, Liu S, Nam R. Predicting High-Risk Disease Using Serum and DNA Biomarkers Current Opinion in Urology. 23: 35-54. PMID 23449497 DOI: 10.1097/Mou.0B013E32835F89B8 |
0.436 |
|
| 2008 |
Liu SK, Olive PL, Bristow RG. Biomarkers for DNA DSB inhibitors and radiotherapy clinical trials. Cancer Metastasis Reviews. 27: 445-58. PMID 18516501 DOI: 10.1007/S10555-008-9137-8 |
0.314 |
|
| 2008 |
Liu SK, Coackley C, Krause M, Jalali F, Chan N, Bristow RG. A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 88: 258-68. PMID 18456354 DOI: 10.1016/J.Radonc.2008.04.005 |
0.332 |
|
| 2001 |
Yoder J, Pham C, Iizuka YM, Kanagawa O, Liu SK, McGlade J, Cheng AM. Requirement for the SLP-76 adaptor GADS in T cell development. Science (New York, N.Y.). 291: 1987-91. PMID 11239162 DOI: 10.1126/Science.1057176 |
0.552 |
|
| Show low-probability matches. |